Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Csl Ltd ADR (CSLLY)

Csl Ltd ADR (CSLLY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
80.9300 +1.4700 (+1.85%) 04/02/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 80.9300 unch (unch) 15:59 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
77.7900
Day High
82.0000
Open 82.0000
Previous Close 79.4600 79.4600
Volume 48,500 48,500
Avg Vol 87,675 87,675
Stochastic %K 65.40% 65.40%
Weighted Alpha -16.10 -16.10
5-Day Change +1.7600 (+2.22%) +1.7600 (+2.22%)
52-Week Range 75.7000 - 109.0000 75.7000 - 109.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 76,950,968
  • Shares Outstanding, K 968,424
  • Annual Sales, $ 14,800 M
  • Annual Income, $ 2,642 M
  • EBIT $ 0 M
  • EBITDA $ 4,750 M
  • 60-Month Beta 0.80
  • Price/Sales 5.17
  • Price/Cash Flow 19.88
  • Price/Book 3.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield 1.28 (1.60%)
  • Most Recent Dividend 0.600 on 03/11/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.7000 +6.91%
on 03/31/25
Period Open: 81.3600
84.2500 -3.94%
on 03/06/25
-0.4300 (-0.53%)
since 02/28/25
3-Month
75.7000 +6.91%
on 03/31/25
Period Open: 87.1600
90.0400 -10.12%
on 01/07/25
-6.2300 (-7.15%)
since 01/02/25
52-Week
75.7000 +6.91%
on 03/31/25
Period Open: 93.1300
109.0000 -25.75%
on 08/28/24
-12.2000 (-13.10%)
since 04/02/24

Most Recent Stories

More News
New Strong Sell Stocks for February 12th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Ares Management Corporation ARES is an alternative asset manager. The Zacks Consensus Estimate for its current year earnings has...

ARES : 154.50 (+3.39%)
CABGY : 25.5300 (+0.35%)
CSLLY : 80.9300 (+1.85%)
3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

GSK : 37.64 (-0.61%)
CSLLY : 80.9300 (+1.85%)
SNY : 53.95 (-0.72%)
CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple...

CSL : 348.23 (+1.47%)
CSLLY : 80.9300 (+1.85%)
Why CSL Ltd Stock Could Be Worth a Look

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

CSL : 348.23 (+1.47%)
CSLLY : 80.9300 (+1.85%)
NVS : 110.77 (+1.06%)
BLUE : 5.03 (-4.19%)
ARCT : 10.20 (+8.17%)
Why Arcturus Therapeutics Stock Is Skyrocketing Today

Investors are applauding Arcturus' collaboration with CSL.

CSL.AX : 257.680 (+0.98%)
CSLLY : 80.9300 (+1.85%)
ARCT : 10.20 (+8.17%)
Finalization of Vifor Pharma acquisition

Regulatory News:

CSL.AX : 257.680 (+0.98%)
OTC.VN : 0.300 (+1.69%)
CSLLY : 80.9300 (+1.85%)
uniQure announces closing of commercialization and license agreement with CSL Behring

Upfront payment of $450 million due to uniQure by May 13, 2021

CSLLY : 80.9300 (+1.85%)
ASX : 9.03 (+0.44%)
QURE : 10.62 (+7.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived...

See More

Key Turning Points

3rd Resistance Point 86.9000
2nd Resistance Point 84.4500
1st Resistance Point 82.6900
Last Price 80.9300
1st Support Level 78.4800
2nd Support Level 76.0300
3rd Support Level 74.2700

See More

52-Week High 109.0000
Fibonacci 61.8% 96.2794
Fibonacci 50% 92.3500
Fibonacci 38.2% 88.4206
Last Price 80.9300
52-Week Low 75.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades